Johnson & Johnson 10-K Summary: Fiscal Year Ended January 1, 2006
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended January 1, 2006. Johnson & Johnson (J&J) is a global healthcare company with approximately 115,600 employees and over 230 operating companies in virtually all countries. The company operates through three primary segments: Consumer (baby care, skin care, OTC pharmaceuticals), Pharmaceutical (prescription drugs across various therapeutic areas), and Medical Devices and Diagnostics (surgical, orthopaedic, and diagnostic products). The company is a large accelerated filer incorporated in New Jersey.
Key Financial Metrics
Note: Specific consolidated revenue, net income, cash flow, and debt figures are incorporated by reference to the Annual Report (Exhibit 13) and are not explicitly detailed in the provided text. The following metrics are available from the filing text:
- Research & Development (R&D) Costs: $6,312 million for fiscal 2005 (charged directly to income).
- Stock Repurchases (Q4 2005): The company purchased approximately 8.96 million shares in the fourth quarter of 2005 at an average price ranging from $61.16 to $62.32 per share.
- Market Capitalization: Approximately $193 billion (as of the last business day of the second fiscal quarter).
- Shares Outstanding: 2,976,068,976 shares as of February 28, 2006.
- Valuation Accounts (Schedule II): Total valuation and qualifying accounts (accrued rebates, doubtful accounts, cash discounts) totaled $2,709 million at the end of 2005.
Material Changes and Operational Highlights
- Patent Expirations and Generic Competition: Sales of DURAGESIC (fentanyl) declined by 23.9% to $1.6 billion in 2005 due to generic competition, primarily in the U.S. EPREX (Epoetin alfa) is also facing or will face generic competition in international markets.
- Key Product Concentration: RISPERDAL and PROCRIT/EPREX accounted for approximately 6% and 7% of total revenues, respectively, in fiscal 2005. Combined sales of DURAGESIC and EPREX accounted for approximately 5% of worldwide sales in 2005.
- Seasonality: Sales do not reflect significant seasonality, though spending is typically heavier in the fourth quarter due to advertising and research grants.
- Manufacturing Footprint: The company operates 142 manufacturing facilities totaling approximately 18.7 million square feet globally.
Guidance, Outlook, Risks, and Contingencies
- Stock Repurchase Program: On March 8, 2006, the Board approved a new program to repurchase up to $5 billion of common stock. The program has no time limit.
- Regulatory Risks: The company faces increasing regulatory stringency regarding product safety, efficacy, and pricing. The FDA requires extensive testing and documentation, increasing the cost of product introduction. There is uncertainty regarding the impact of the Medicare Prescription Drug, Improvement and Modernization Act.
- Legal Proceedings: The company is involved in various proceedings under the Comprehensive Environmental Response, Compensation and Liability Act (Superfund). Management believes these will not have a material adverse effect on financial position.
- Internal Controls: Management concluded that internal controls over financial reporting were effective as of January 1, 2006, based on COSO criteria. This assessment was audited by PricewaterhouseCoopers LLP.
Investor Verification Checklist
- Verify the full consolidated revenue, net income, and cash flow figures in the Annual Report (Exhibit 13), as they are not explicitly listed in the 10-K text provided.
- Review the impact of the DURAGESIC patent expiration on future Pharmaceutical segment margins.
- Monitor the execution of the new $5 billion stock repurchase program announced in March 2006.
- Assess the timeline for RISPERDAL patent expiration (scheduled for December 2007 in the U.S.) and potential pediatric extensions.
- Examine the Legal Proceedings note (pages 57-63 of the Annual Report) for details on environmental liabilities and product liability litigation.